Abnova (Taiwan) Corporation

Equities

4133

TW0004133004

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
33.45 ^TWD	+3.40%		+4.21%	-4.70%

05-09	Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-08	Abnova Corporation Announces Establishment of Risk Management Committee	CI

Abnova Corporation Announces Establishment of Risk Management Committee

May 08, 2024 at 08:20 am

Abnova (Taiwan) Corporation announced establishment of Risk Management Committee. Name of the new position holder: Cha Anna, Ye Shao De and Su Jin Jun. Resume of the new position holder: Cha Anna: Independent Director.

Chairman of Rouge Creative Marketing Co. Chairman of Chipcom International Co.,Ltd. Ye Shao De: Independent Director. Chairman of Cancer Center,Taipei Medical University Hospital.

Director, Prostate Center of Excellence, Taipei Medical University Hospital. Su Jin Jun. Independent Director.

Professor and Dean of School of International Business, TKK College, Xiamen University. Effective date of the new member is May 8, 2024. Reason for the change: New appointment.

Latest news about Abnova (Taiwan) Corporation

Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Abnova Corporation Announces Establishment of Risk Management Committee	05-08	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Abnova Corporation Approves Cash Dividend for the Year Ended December 31, 2023, Payable on June 27, 2024	02-20	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Abnova Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/08/23	CI
Abnova Corporation Announces Dividend Distribution for 2022, Payment on 5 July 2023	31/05/23	CI
Abnova Corporation Elects Members of the Company's Remuneration Committee	15/05/23	CI
Abnova Corporation Elects Members of the Company's Audit Committee	15/05/23	CI
Abnova Corporation Elects Board Members	15/05/23	CI
Abnova Corporation Approves Dividend Distribution for the Year 2022	15/05/23	CI
Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	01/03/23	CI
Abnova Corporation Announces Change of President	24/02/23	CI
Abnova Corporation Approves Dividend Distribution for the Year 2022	24/02/23	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Abnova Corporation(TWSE:4133) dropped from S&P Global BMI Index	19/09/22	CI
Abnova Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	04/05/22	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/11/21	CI
Abnova Taiwan Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	10/08/21	CI
Abnova Taiwan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	03/05/21	CI
Abnova Taiwan Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	29/03/21	CI
Abnova Taiwan Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	10/11/20	CI

Chart Abnova (Taiwan) Corporation

Duration

Period

More charts

Company Profile

ABNOVA (TAIWAN) CORPORATION is a Taiwan-based company principally engaged in the manufacturing and sales of antibodies and proteins. The Company's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The Company's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABNOVA (TAIWAN) CORPORATION	-4.70%	62.28M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs